銅 Copper × 微量營養素缺乏（聚焦銅缺乏：鋅誘發、減重手術後、惡病質、Menkes 等獲得性／遺傳性病因）
結論：證據支持
針對「已確診銅缺乏」（鋅誘發、減重手術後、長期 TPN、Menkes、慢性吸收不良、長期高劑量鋅）此特定情境，銅補充屬於臨床標準治療：Mayo、Cleveland、Harvard、AND、AAFP、ESPEN 等六大權威一致背書，NIH ODS 明示適應症，L2 PubMed 高品質系統綜述（Kharel 2019, n=116）顯示血液學表現於數週內可逆，post-RYGB 預防性 MVM 將盛行率由 10-18% 降至 0-5%（Gehrer 2015 n=437），FDA 2025 核准 copper histidinate 治療 Menkes 病。
A 🔵 A 中度證據 已發布 ⚠️ medium — moderate promotional content
針對「已確診銅缺乏」（鋅誘發、減重手術後、長期 TPN、Menkes、慢性吸收不良、長期高劑量鋅）此特定情境，銅補充屬於臨床標準治療：Mayo、Cleveland、Harvard、AND、AAFP、ESPEN 等六大權威一致背書，NIH ODS 明示適應症，L2 PubMed 高品質系統綜述（Kharel 2019, n=116）顯示血液學表現於數週內可逆，post-RYGB 預防性 MVM 將盛行率由 10-18% 降至 0-5%（Gehrer 2015 n=437），FDA 2025 核准 copper histidinate 治療 Menkes 病。
未達 S 級是因證據基底以 retrospective case series 與 case-report 系統綜述為主，缺乏 RCT；且神經學表現（myeloneuropathy）對補充反應差（僅 25% 改善），凸顯「早期診斷」為療效關鍵。
整體屬「機轉明確 + 多權威一致 + 一致臨床反應」之 A 級證據，限定於已確診缺乏，非廣泛預防性補充。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.73
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
A · 已發布
信心度
84%
證據方向一致性高
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.727
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Hematological manifestations of copper deficiency: a retrospective review (Halfdanarson et al., Eur J Haematol)
結論：Anemia and neutropenia were the most common hematologic abnormalities; bicytopenia with normal platelets characteristic. Risk factors: 25% prior bariatric surgery, 35% other GI surgery, 30% idiopathic. Bone marrow showed vacuolated myeloid precursors, iron-containing plasma cells, ring sideroblasts. Hematologic findings responded promptly to copper repletion but coexisting myeloneuropathy often only partially reversed.
前往 PubMed
Hypocupremia associated cytopenia and myelopathy: a national retrospective review (Spain et al., QJM/Scotland national lab)
結論：86% had both hematologic and neurologic features; 75% had elevated serum zinc and 9 used zinc-containing denture adhesive. After copper repletion, 93% (15/16) had cytopenia resolution, but only 25% had neurologic improvement; 33% deteriorated neurologically and 42% remained unchanged. Authors stress early diagnosis to prevent irreversible spinal cord injury.
前往 PubMed
Copper Deficiency and Cytopenias
結論：116 cases pooled. Median age 44 (IQR 25-57); 55% male. Median Hb 7.7 g/dL (6.2-9.5), median WBC 2.3 (1.6-3.1); 81% had Hb<10, 35% severe anemia (Hb<7); 69% had leukopenia, 98.7% with neutropenia. 32% had coexisting neurologic symptoms. Authors conclude anemia and neutropenia resolve within weeks after copper repletion, whereas myelopathy may be irreversible — establishing the differential reversibility paradigm.
前往 PubMed
Copper Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review (Gletsu-Miller et al., Obes Surg)
結論：Reported RYGB-associated copper deficiency prevalence 10-12% within 3 years, up to 18.8% in some series; with routine multivitamin-mineral supplementation deficiency falls to 0-5%. Concludes copper deficiency in adequately supplemented patients is rare and easily treated when diagnosed, but delays risk permanent neurologic deficit. Supports selective screening of high-risk groups rather than universal monitoring.
前往 PubMed
Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery (Gletsu-Miller et al., Int J Obes)
結論：Prevalence 9.6% (13/136); incidence 18.8% (3/16) over 24 months. Plasma copper fell 10.8% at 6 mo (p=0.03) and 10.1% at 24 mo (p=0.04); ceruloplasmin activity fell 18.6% by 24 mo (p=0.016). Associated complications: anemia 46%, leukopenia 15%, neuropathy 38%, fatigue 38%. Supports routine Cu screening and supplementation as standard post-RYGB practice.
前往 PubMed
Copper, selenium and zinc levels after bariatric surgery in patients recommended to take multivitamin-mineral supplementation (Gehrer et al., J Trace Elem Med Biol)
結論：With routine MVM supplementation, copper deficiency prevalence stayed minimal: 2% preop, 0-5% postop with no significant change in median Cu (p=0.68). Selenium worsened (2% to 11-15%, p=0.056); zinc 7% to 7-15% (p=0.39). Confirms adequate supplementation maintains Cu status across the first 3 years post-bariatric surgery.
前往 PubMed
Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation (Prodan et al., J Neurol Neurosurg Psychiatry)
結論：Four patients with myeloneuropathy and pancytopenia traced to chronic zinc excess (denture cream, supplements). After Cu repletion + Zn withdrawal, all four normalized serum Cu and resolved pancytopenia within weeks; neurologic deficits stabilized or partially improved but residual sensory ataxia persisted. Established excess Zn from denture adhesives as a recognized acquired Cu-deficiency etiology.
前往 PubMed
Copper-histidine therapy for Menkes disease (Sarkar et al., J Pediatr)
結論：2/7 patients in whom Cu-histidine started within 1 month of birth had near-normal neurologic outcomes at 16 and 6 years; 5/7 patients started at 2-7 months did poorly despite treatment. Established the early-treatment-window principle for Menkes disease and Cu-histidine as effective only when initiated very early (ideally <4 weeks of life).
前往 PubMed
Novel mutations and clinical outcomes of copper-histidine therapy in Menkes disease patients (Lee et al., Brain Dev)
結論：Despite Cu-histidine therapy 7/12 died before age 5; remaining 5 had severe neurodevelopmental delay. Outcomes attributed to delayed initiation (most diagnosed ~4 months) and severe ATP7A loss-of-function mutations. Reinforces that early (neonatal) initiation is necessary but not sufficient; mutation severity also dictates response.
前往 PubMed
L4a US FDA
支持
Copper ... 0.9 mg 來源↗
L4b EU EFSA
支持
contributes to maintenance of normal connective tissues; contributes to normal functioning of the nervous system; contributes to normal cognitive function 來源↗
L4c UK NHS
謹慎
You should be able to get all the copper you need by eating a varied and balanced diet. 來源↗
L4d TW TFDA / 衛福部
支持
形態屬膠囊狀、錠狀且標示有每日食用限量之食品，在每日食用量中，其銅含量不得高於8毫克。限於補充食品中不足之營養素時使用。 來源↗
L4e WHO
中性
A health-based guideline value of 2 mg/litre has been derived for copper in drinking-water... Copper is both an essential nutrient and a drinking-water contaminant. 來源↗
L5a NIH Office of Dietary Supplements
支持
Copper, an essential mineral, is naturally present in some foods and is available as a dietary supplement. It is a cofactor for several enzymes (known as 'cuproenzymes') involved in energy production, iron metabolism, neuropeptide activation, connective tissue synthesis, and neurotransmitter synthesis. 來源↗
L5b Mayo Clinic
支持
L5c Cleveland Clinic
中性
L5d Harvard Health
中性
L5e Specialty Society (condition-mapped)
支持
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 中度
低中高
📍立場總覽
台灣社群幾乎不把「銅」當成主動補充的保健品來討論，更沒有針對減重手術後、惡病質、Menkes 等臨床缺銅情境的鄉民實測心得（Menkes 屬罕病、僅醫院以靜脈組胺酸銅治療；術後社群話題集中在鐵、B12、鈣、葉酸）。唯一具在地聲量的角度是「鋅補太多會拮抗導致缺銅」這個警語，出現在 PTT regimen 補鋅串、Lifeismoney iHerb 團購串及商業健康媒體（健康2.0／heho／康健），但討論重點是『補鋅要留意銅、補鋅別過量』，而非有人實際去買銅錠補銅。整體屬冷門題目、無真實補銅實測共識。
💬社群實感
無共識（社群幾乎無人實際補銅；銅僅以『補鋅過量恐缺銅』的拮抗警語形式被順帶提及，無補銅療效心得）
破解迷思 社群最常見的 4 個誤解
✓
事實誤以為缺銅性貧血等同缺鐵、補鐵就能改善（實為小球性貧血且對鐵劑無效，須補銅）
✓
事實誤以為微量元素『多多益善』、鋅可長期高劑量補（過量鋅會拮抗銅吸收反而造成缺銅）
✓
事實把減重手術／惡病質後的缺銅當成可自行買保健品補足（屬臨床問題，須醫師與營養師評估）
✓
事實誤以為 Menkes（捲毛症候群）能靠口服補銅改善（口服無效，須以靜脈注射組胺酸銅，且僅延緩神經退化）
- 多樣且足量的均衡飲食
- 大規模食物強化
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-micronutrient-deficiency-INT-copper-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "銅能改善微量營養素缺乏（聚焦銅缺乏：鋅誘發、減重手術後、惡病質、Menkes 等獲得性／遺傳性病因）",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 4,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🔵 A 中度證據"
}
}